Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLCG1 | P19174 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.41 |
| ▸ | PDK3 | Q15120 | 2/20 | 0.41 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.39 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3822998 | 0.86 | PLCG1 (0.49) | PLCG1MEN1KMT2ALMNAPDK1 | |
| SCHEMBL30966610 | 0.86 | PLCG1 (0.49) | PLCG1MEN1KMT2ALMNAPDK1 | |
| SCHEMBL1626668 | 0.83 | PLCG1 (0.44) | PLCG1MEN1KMT2AMAPK1LMNA | |
| SCHEMBL30938845 | 0.83 | PDK1 (0.46) | MEN1KMT2AMAPK1LMNAPDK1 | |
| SCHEMBL1627733 | 0.80 | TSHR (0.47) | MEN1KMT2AMAPK1LMNAPDK1 | |
| SCHEMBL25845024 | 0.75 | PLCG1 (0.46) | PLCG1MEN1KMT2AMAPK1LMNA | |
| SCHEMBL25845063 | 0.75 | PDK1 (0.42) | PLCG1MEN1KMT2AMAPK1LMNA | |
| SCHEMBL27801144 | 0.74 | PLCG1 (0.51) | PLCG1NPSR1TSHRKCNN4 | |
| SCHEMBL31612950 | 0.74 | LMNA (0.47) | PLCG1MEN1KMT2ALMNAPDK1 | |
| SCHEMBL10334903 | 0.74 | LMNA (0.43) | MEN1KMT2ALMNACNR2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7928139-B2 | Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof | AMGEN INC. (US) | 2011-04-19 | — | — | US | disclosed |
| US-20100048572-A1 | NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF | AMGEN INC. (US) | 2010-02-25 | — | — | US | disclosed |
| US-7635715-B2 | Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof | AMGEN INC. (US) | 2009-12-22 | — | — | US | disclosed |
| EP-2111399-A2 | NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF | Amgen Inc. (US) | 2009-10-28 | — | — | EP | disclosed |
| US-20090093483-A1 | Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof | AMGEN INC. (US) | 2009-04-09 | — | — | US | disclosed |
| WO-2008076427-A2 | NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF | AMGEN INC. (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048572-A1 | NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF | EGLN2, EGLN3, HIF1AN | PLCG1 4384/4885MEN1 3465/4885KMT2A 1695/4885 |
| US-20090093483-A1 | Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof | EGLN2, EGLN3, HIF1AN | PLCG1 4384/4885MEN1 3465/4885KMT2A 1695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.